Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Autism Spectrum Disorder (autistic disorder, pervasive developmental disorder not otherwise specified), Asperger's disorder) based upon an Autism Diagnostic Observation Scale (ADOS) and Diagnostic and Statistical Manual (DSM-IV) interview.~2. Minimum of 1 month on a stable atypical antipsychotic dose with no plans to change the dose for the next 4 months.~3. A documented greater than/equal to 7% increase in BMI since starting atypical antipsychotic therapy(going back as far as prior 12 months); or, if BMI is greater or equal to 85th percentile corrected for age and sex, then a greater than 5% body weight increase per year (prorated at greater than 5% body weight increase if medicated for longer than a year).~4. Age 6 years to 17 years, 4 months.~5. Subjects and their parents (guardians) must be judged reliable for medication compliance and must agree to keep appointments for study visits and tests as outlined in the protocol.~6. Prior to the conduct of any study-specific procedures, the subject must provide assent to participate in the study (if developmentally appropriate), and their parents (guardians) must provide written informed consent.~Exclusion Criteria:~1. History of intolerable adverse effects with metformin.~2. Prior history of an exposure to metformin of sufficient dose or duration to determine response status.~3. History of liver disease, renal impairment, congestive heart failure, pernicious anemia, any other condition increasing the risk for lactic acidosis, or any serious medical illness requiring treatment.~4. Use of cationic drugs excreted by the kidneys.~5. Planned surgery or procedure requiring contrast.~6. Pregnant at screening contact.~7. On other psychotropic concomitant medications for less than 2 months.~8. Treatment or planned treatment with concomitant medications with unacceptable interactions with metformin, including topiramate, levetiracetam, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, diuretics, or histamine H2 receptor antagonists.~9. Unable to tolerate blood work.~10. Current use of medication for target symptoms of appetite or weight loss.~11. Planned change of medication, medication dose, or behavioral treatment targeting weight loss during the study period.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Hydrochloride Oral Solution (Type: PLACEBO_COMPARATOR): None
- Metformin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).